Lentinan: Hematopoietic, Immunological, and Efficacy Studies in a Syngeneic Model of Acute Myeloid Leukemia

被引：26

作者：

McCormack, Emmet ^{[1
]}

Skavland, Jorn ^{[1
]}

Mujic, Maja ^{[1
]}

Bruserud, Oystein ^{[1
]}

Gjertsen, Bjorn Tore ^{[1
]}

机构：

[1] Univ Bergen, Haematol Sect, Haukeland Univ Hosp, Inst Med, N-5021 Bergen, Norway

来源：

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | 2010年 / 62卷 / 05期

关键词：

ACUTE MYELOGENOUS LEUKEMIA; PATTERN-RECOGNITION RECEPTOR; TUMOR-NECROSIS-FACTOR; BETA-GLUCAN; IN-VIVO; MONOCLONAL-ANTIBODIES; CURATIVE RESECTION; SURVIVAL-TIME; STEM-CELLS; CANCER;

D O I：

10.1080/01635580903532416

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lentinan, a -glucan nutritional supplement isolated from the shitake mushroom (Lentula edodes), is a biological response modifier with immunostimulatory properties. Concomitantly, the role of -glucans as chemoimmunotherapeutic in a number of solid cancers has been widely documented. We investigated the effects of nutritional grade lentinan upon BN rats and in a preclinical syngeneic model of acute myeloid leukemia. BN rats supplemented daily with lentinan exhibited weight gains, increased white blood cells, monocytes, and circulating cytotoxic T-cells; and had a reduction in anti-inflammatory cytokines IL-4, IL-10, and additionally IL-6. Lentinan treatment of BN rats with BNML leukemia resulted in improved cage-side health and reduced cachexia in the terminal stage of this aggressive disease. Combination of lentinan with standards of care in acute myeloid leukemia, idarubicin, and cytarabine increased average survival compared with monotherapy and reduced cachexia. These results indicate that nutritional supplementation of cancer patients with lentinan should be further investigated.

引用

页码：574 / 583

页数：10

共 48 条

[1] Monoclonal antibodies for the treatment of acute myeloid leukemia [J].

Abutalib, Syed A. ;

Tallman, Martin S. .

CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (05) :343-369

[2]

Akimoto M, 1984, Gan To Kagaku Ryoho, V11, P1462

[3] Immune recognition of fungal β-glucans [J].

Brown, GD ;

Gordon, S .

CELLULAR MICROBIOLOGY, 2005, 7 (04) :471-479

[4]

Brown GD, 2006, NAT REV IMMUNOL, V6, P33, DOI 10.1038/nri1745

[5]

Bruserud O, 2001, EXPERT OPIN BIOL TH, V1, P1005

[6]

CARELLA AM, 1993, LEUKEMIA, V7, P196

[7] Effects of supplementation of β-glucan on the growth performance and immunity in broilers [J].

Chae, BJ ;

Lohakare, JD ;

Moon, WK ;

Lee, SL ;

Park, YH ;

Hahn, TW .

RESEARCH IN VETERINARY SCIENCE, 2006, 80 (03) :291-298

[8] An immune edited tumour versus a tumour edited immune system:: prospects for immune therapy of acute myeloid leukaemia [J].

Chan, L ;

Hardwick, NR ;

Guinn, BA ;

Darling, D ;

Gäken, J ;

Galea-Lauri, J ;

Ho, AY ;

Mufti, GJ ;

Farzaneh, F .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (08) :1017-1024

[9] Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies [J].

Cheung, NKV ;

Modak, S ;

Vickers, A ;

Knuckles, B .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (10) :557-564

[10] β-Glucan enhances complement-mediated hematopoietic recovery after bone marrow injury [J].

Cramer, DE ;

Allendorf, DJ ;

Baran, JT ;

Hansen, R ;

Marroquin, J ;

Li, B ;

Ratajczak, J ;

Ratajczak, MZ ;

Yan, J .

BLOOD, 2006, 107 (02) :835-840

← 1 2 3 4 5 →